Neurocrine’s Ingrezza flunks pivotal study in dyskinetic cerebral palsy
Neurocrine Biosciences’ Ingrezza has failed a late-stage trial in a type of cerebral palsy, adding to a spate of clinical disappointments for the biotech in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Read More from Endpoints News